Murine norovirus (MNV-1) exposure in vitro to the purine nucleoside analog Ribavirin increases quasispecies diversity (Q38825741)

6 September 2017

title

Murine norovirus (MNV-1) exposure in vitro to the purine nucleoside analog Ribavirin increases quasispecies diversity (English)

1 reference

6 September 2017

1 reference

1 reference

1 reference

1 reference

1

1 reference

6 September 2017

5

Abimbola O Kolawole

1 reference

6 September 2017

7

Christiane E Wobus

1 reference

6 September 2017

2

Joseph D Baugher

1 reference

6 September 2017

3

Christine M Rippinger

1 reference

6 September 2017

Rebecca Pinekenstein

4

1 reference

6 September 2017

Thomas S Mehoke

6

1 reference

6 September 2017

Andrew B Feldman

8

1 reference

6 September 2017

Fernando J Pineda

9

1 reference

6 September 2017

Kellogg J Schwab

10

1 reference

6 September 2017

language of work or name

1 reference

19 October 2015

1 reference

6 September 2017

1 reference

6 September 2017

volume

211

1 reference

6 September 2017

page(s)

165-173

1 reference

Viral error catastrophe by mutagenic nucleosides

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/J.VIRUSRES.2015.10.016

Favipiravir elicits antiviral mutagenesis during virus replication in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VIRUSRES.2015.10.016

Evaluation of murine norovirus, feline calicivirus, poliovirus, and MS2 as surrogates for human norovirus in a model of viral persistence in surface water and groundwater

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VIRUSRES.2015.10.016

Ribavirin: a drug active against many viruses with multiple effects on virus replication and propagation. Molecular basis of ribavirin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VIRUSRES.2015.10.016

Rapid evolution of pandemic noroviruses of the GII.4 lineage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VIRUSRES.2015.10.016

Interferons and ribavirin effectively inhibit Norwalk virus replication in replicon-bearing cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VIRUSRES.2015.10.016

Analysis of Ribavirin Mutagenicity in Human Hepatitis C Virus Infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VIRUSRES.2015.10.016

Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VIRUSRES.2015.10.016

Implications of high RNA virus mutation rates: lethal mutagenesis and the antiviral drug ribavirin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VIRUSRES.2015.10.016

RNA virus error catastrophe: direct molecular test by using ribavirin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VIRUSRES.2015.10.016

The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VIRUSRES.2015.10.016

Error-prone replication of West Nile virus caused by ribavirin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VIRUSRES.2015.10.016

Deep sequencing reveals mutagenic effects of ribavirin during monotherapy of hepatitis C virus genotype 1-infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VIRUSRES.2015.10.016

Antiviral strategy on the horizon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VIRUSRES.2015.10.016

RNA virus mutations and fitness for survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VIRUSRES.2015.10.016

Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VIRUSRES.2015.10.016

Treatment of severe acute hepatitis E by ribavirin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VIRUSRES.2015.10.016

Quasispecies, error catastrophe, and the antiviral activity of ribavirin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VIRUSRES.2015.10.016

Mechanisms of action of ribavirin against distinct viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VIRUSRES.2015.10.016

Lethal mutagenesis of poliovirus mediated by a mutagenic pyrimidine analogue.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VIRUSRES.2015.10.016

Lethal mutagenesis of picornaviruses with N-6-modified purine nucleoside analogues.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VIRUSRES.2015.10.016

Suppression of viral infectivity through lethal defection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VIRUSRES.2015.10.016

Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VIRUSRES.2015.10.016

KP-1212/1461, a nucleoside designed for the treatment of HIV by viral mutagenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VIRUSRES.2015.10.016

Mutagenic effect of ribavirin on hepatitis C nonstructural 5B quasispecies in vitro and during antiviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VIRUSRES.2015.10.016

Effects of ribavirin on respiratory syncytial virus in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VIRUSRES.2015.10.016

Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VIRUSRES.2015.10.016

The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5'-triphosphate towards influenza A virus polymerase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VIRUSRES.2015.10.016

The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VIRUSRES.2015.10.016

Ribavirin reduces mortality in enterovirus 71-infected mice by decreasing viral replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VIRUSRES.2015.10.016

Lethal mutagenesis of HIV with mutagenic nucleoside analogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VIRUSRES.2015.10.016

Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VIRUSRES.2015.10.016

Lassa fever. Effective therapy with ribavirin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VIRUSRES.2015.10.016

Depletion of GTP pool is not the predominant mechanism by which ribavirin exerts its antiviral effect on Lassa virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VIRUSRES.2015.10.016

Extinction of hepatitis C virus by ribavirin in hepatoma cells involves lethal mutagenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VIRUSRES.2015.10.016

Systematic literature review of role of noroviruses in sporadic gastroenteritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VIRUSRES.2015.10.016

Lethal mutagenesis of foot-and-mouth disease virus involves shifts in sequence space

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VIRUSRES.2015.10.016

A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VIRUSRES.2015.10.016

Lethal mutagenesis of the prototypic arenavirus lymphocytic choriomeningitis virus (LCMV).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VIRUSRES.2015.10.016

Treatment of persistent rhinovirus infection with pegylated interferon α2a and ribavirin in patients with hypogammaglobulinemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VIRUSRES.2015.10.016

Response of foot-and-mouth disease virus to increased mutagenesis: influence of viral load and fitness in loss of infectivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VIRUSRES.2015.10.016

Murine noroviruses comprising a single genogroup exhibit biological diversity despite limited sequence divergence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VIRUSRES.2015.10.016

Ribavirin and lethal mutagenesis of poliovirus: molecular mechanisms, resistance and biological implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VIRUSRES.2015.10.016

Replication of Norovirus in cell culture reveals a tropism for dendritic cells and macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VIRUSRES.2015.10.016

The role of chronic norovirus infection in the enteropathy associated with common variable immunodeficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VIRUSRES.2015.10.016

10.1016/J.VIRUSRES.2015.10.016

7 January 2021

Identifiers

DOI

1 reference

6 September 2017

1 reference